Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$15.30 USD
-0.38 (-2.42%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $15.32 +0.02 (0.13%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Brokerage Reports
Urogen Pharma [URGN]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Positive UGN-102 Long-Term Complete Response Rate Data; Raising PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 ENVISION Pivotal Data Next Month; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Additional Clinical Analyses Presented at AUA 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
AUA Showcases Next Month; UGN-103 Cleared for Clinical Entry; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Patent Infringement Suit Filed; HCW@Home Recap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 Rolling Submission Completion Nears; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Exclusive License to Possible Next-Gen Mitomycin Formulation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for URGN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 12-Month Data Next Year; 3Q23 Earnings Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 New Drug Application Rolling Submission Timeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Record Revenue, Modest Bottom-Line Beat; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
ATLAS and ENVISION Data Surpass Expectations; Raising PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Favorable Jelmyto Retrospective Study Results Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Top-Line Beat, Bottom-Line In-Line; Adjusting Sales Forecast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Study Results Underscore Jelmyto Utility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Top-Line Beat; Revenue Growth Guidance Lukewarm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Feasibility Study Shows Potential for UGN-102 In-Home Usage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R